Erdafitinib

Introduction: What is Erdafitinib?

Erdafitinib is a targeted therapy medication primarily used in the treatment of certain types of bladder cancer. Specifically, it is indicated for patients with locally advanced or metastatic urothelial carcinoma who have specific genetic mutations known as FGFR2 or FGFR3 alterations. Erdafitinib works by inhibiting the fibroblast growth factor receptor (FGFR), which plays a crucial role in cancer cell growth and survival. By blocking this receptor, Erdafitinib helps to slow down or stop the progression of cancer.

Uses of Erdafitinib

Erdafitinib is approved for the treatment of:

• Locally Advanced Urothelial Carcinoma: This includes cancer that has spread to nearby tissues but not to distant parts of the body.
• Metastatic Urothelial Carcinoma: This refers to cancer that has spread to other parts of the body.
• FGFR Alterations: It is specifically indicated for patients whose tumors have specific genetic changes in the FGFR2 or FGFR3 genes, identified through an FDA-approved companion diagnostic test.

How It Works

Erdafitinib functions by targeting and inhibiting the activity of fibroblast growth factor receptors (FGFRs) on the surface of cancer cells. In simpler terms, FGFRs are like "on" switches that help cancer cells grow and divide. By blocking these receptors, Erdafitinib effectively turns off the signals that promote cancer cell growth, leading to reduced tumor size and potentially slowing the progression of the disease.

Dosage and Administration

Erdafitinib is typically administered in tablet form. The standard dosage for adults is:

• Initial Dose: 8 mg taken once daily.
• Adjustment: Depending on the patient's tolerance and side effects, the dose may be adjusted to 6 mg or increased to 9 mg or 12 mg daily.

For pediatric patients, the safety and efficacy of Erdafitinib have not been established, and it is not recommended for use in children.

Side Effects of Erdafitinib

Common side effects may include:

• Fatigue
• Nausea
• Diarrhea
• Decreased appetite
• Dry mouth

Serious side effects can include:

• Vision changes (blurred vision, dry eyes)
• Liver problems (elevated liver enzymes)
• Hyperphosphatemia (high phosphate levels in the blood)
• Serious infections

Patients should report any unusual symptoms to their healthcare provider promptly.

Drug Interactions

Erdafitinib may interact with several medications, including:

• CYP3A4 Inhibitors: Such as ketoconazole, which can increase the levels of Erdafitinib in the body.
• CYP3A4 Inducers: Such as rifampin, which can decrease the effectiveness of Erdafitinib.
• Other Cancer Therapies: Always inform your doctor about any other medications you are taking to avoid potential interactions.

Benefits of Erdafitinib

The clinical advantages of using Erdafitinib include:

• Targeted Therapy: It specifically targets cancer cells with FGFR mutations, potentially leading to better outcomes with fewer side effects compared to traditional chemotherapy.
• Oral Administration: Being an oral medication, it offers convenience and ease of use for patients.
• Potential for Improved Survival: Clinical studies have shown that Erdafitinib can lead to significant tumor shrinkage and improved survival rates in patients with specific bladder cancers.

Contraindications of Erdafitinib

Erdafitinib should be avoided in the following situations:

• Pregnancy: It may cause fetal harm; effective contraception is recommended during treatment and for a period after the last dose.
• Allergic Reactions: Individuals with known hypersensitivity to Erdafitinib or any of its components should avoid it.

Precautions and Warnings

Before starting Erdafitinib, patients should undergo:

• Vision Tests: Regular eye examinations are recommended, as vision changes can occur.
• Liver Function Tests: Use with caution in patients with severe hepatic impairment, as clinical data are limited.
• Phosphate Levels: Regular blood tests to check phosphate levels are necessary, as Erdafitinib can cause hyperphosphatemia. Hyperphosphatemia is a common on-target effect and requires regular monitoring and dietary or pharmacologic management.

FAQs

• What is Erdafitinib used for? Erdafitinib is used to treat certain types of bladder cancer, specifically in patients with FGFR2 or FGFR3 mutations.
• How is Erdafitinib taken? It is taken orally in tablet form, usually once daily.
• What are the common side effects? Common side effects include fatigue, nausea, diarrhea, and decreased appetite.
• Can Erdafitinib be used in children? No, its safety and efficacy in pediatric patients have not been established.
• What should I do if I miss a dose? If you miss a dose, take it as soon as you remember. If it's close to the next dose, skip the missed dose and continue with your regular schedule.
• Are there any serious side effects? Yes, serious side effects can include vision changes, liver problems, and high phosphate levels.
• Can I take other medications with Erdafitinib? Always inform your doctor about all medications you are taking to avoid potential interactions.
• Is there a risk of pregnancy while taking Erdafitinib? Yes, it is contraindicated in pregnancy due to potential harm to the fetus.
• How often should I have my liver checked? Your doctor will determine the frequency of liver function tests based on your treatment plan.
• What should I do if I experience side effects? Contact your healthcare provider immediately if you experience any unusual or severe side effects.

Brand Names

Erdafitinib is marketed under the brand name Balversa.

Conclusion

Erdafitinib represents a significant advancement in the treatment of bladder cancer, particularly for patients with specific genetic mutations. Its targeted mechanism of action, oral administration, and potential for improved outcomes make it a valuable option in oncology. However, like all medications, it comes with risks and side effects that require careful management. Always consult with your healthcare provider to determine if Erdafitinib is the right choice for your treatment plan.